In a 10-observation write-up, the FDA chided Dr. Reddy’s for missteps around building and equipment maintenance, deficient quality control activities, mishandling of complaints and more.

Following an inspection of Piramal’s production facility in Maharashtra, India, that ran from Feb. 11 to Feb. 17, the FDA slapped the company with six-observation Form 483 detailing shortfalls ...